CONSOLIDATED STATEMENTS OF CONVERTIBLE PREFERRED SHARES AND SHAREHOLDERS' EQUITY (DEFICIT) - USD ($) $ in Thousands		Total	Reverse Recapitalization Of GlycoMimetics	Series A Preferred Stock	Convertible Notes Payable	Convertible Preferred Stock	Non-Voting Preferred Shares	Non-Voting Preferred Shares Series A Preferred Stock	Ordinary Shares	Ordinary Shares Reverse Recapitalization Of GlycoMimetics	Ordinary Shares Convertible Notes Payable	Additional Paid-in Capital	Additional Paid-in Capital Reverse Recapitalization Of GlycoMimetics	Additional Paid-in Capital Convertible Notes Payable	Accumulated Deficit
Beginning balance, Convertible Preferred Stock (in shares) at Sep. 19, 2024						0
Beginning balance, Convertible Preferred Stock at Sep. 19, 2024						$ 0
Increase (Decrease) in Temporary Equity [Roll Forward]
Issuance of Series Seed convertible preferred stock (in shares)						20,000,000
Issuance of Series Seed convertible preferred stock						$ 4,000
Ending balance, Convertible Preferred Stock (in shares) at Dec. 31, 2024						20,000,000
Ending balance, Convertible Preferred Stock at Dec. 31, 2024						$ 4,000
Beginning balance (in shares) at Sep. 19, 2024							0
Beginning balance at Sep. 19, 2024		$ 0					$ 0		$ 0			$ 0			$ 0
Beginning balance (in shares) at Sep. 19, 2024									0
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of common stock (in shares)	[1]								1,018,604
Issuance of common stock	[1]	1,315							$ 1			1,314
Share-based compensation		1,073										1,073
Net loss		(17,867)													(17,867)
Ending balance (in shares) at Dec. 31, 2024				0			0
Ending balance at Dec. 31, 2024		$ (15,479)					$ 0		$ 1			2,387			(17,867)
Ending balance (in shares) at Dec. 31, 2024		1,018,604							1,018,604
Increase (Decrease) in Temporary Equity [Roll Forward]
Exchange of Series Seed convertible preferred stock for Series A designated non-voting convertible preferred shares upon the closing of the reverse recapitalization (in shares)						(20,000,000)
Exchange of Series Seed convertible preferred stock for Series A designated non-voting convertible preferred shares upon the closing of the reverse recapitalization						$ (4,000)
Ending balance, Convertible Preferred Stock (in shares) at Dec. 31, 2025						0
Ending balance, Convertible Preferred Stock at Dec. 31, 2025						$ 0
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of common stock (in shares)									13,664,251
Issuance of common stock		$ 185,000							$ 14			184,986
Repurchase and cancellation of restricted stock awards (in shares)									(127,889)
Repurchase and cancellation of restricted stock awards		(177)										(177)
Conversion of convertible securities (in shares)								2,890		645,274	1,850,790
Conversion of convertible securities			$ 525	$ 4,000	$ 40,515			$ 4,000			$ 2		$ 525	$ 40,513
Issuance of common stock and pre-funded warrants in the Pre-Closing financing (in shares)									10,504,926
Issuance of ordinary shares and pre-funded warrants in the Pre-Closing financing		159,475							$ 11			159,464
Issuance costs of Pre-closing financing and reverse recapitalization		(17,201)										(17,201)
Issuance costs of private placement financing		(13,065)										(13,065)
Issuance of Parascent warrants		4,358										4,358
Share-based compensation		$ 9,003										9,003
Early exercise of stock options (in shares)		811							811
Net loss		$ (153,942)													(153,942)
Ending balance (in shares) at Dec. 31, 2025				2,890			2,890
Ending balance at Dec. 31, 2025		$ 203,012					$ 4,000		$ 28			$ 370,793			$ (171,809)
Ending balance (in shares) at Dec. 31, 2025		27,556,767							27,556,767

[1] Includes issuance of 296,104 restricted stock awards (see Note 10)